Abstract
The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
